Sugammadex
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery
Conditions
Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery
Trial Timeline
May 13, 2017 → Oct 10, 2020
NCT ID
NCT03196167About Sugammadex
Sugammadex is a approved stage product being developed by Merck for Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT03196167. Target conditions include Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05276804 | Phase 3 | Completed |
| NCT03196167 | Approved | Completed |
| NCT02011490 | Phase 1 | Completed |
| NCT00826176 | Phase 3 | Completed |
| NCT00702715 | Phase 3 | Completed |
| NCT00535496 | Phase 3 | Completed |
| NCT00591786 | Phase 2 | Completed |
| NCT00552929 | Phase 2 | Completed |
| NCT00482599 | Phase 3 | Completed |
Competing Products
20 competing products in Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery